http://dx.doi.org/10.14288/1.0449009
department or school: Medicine, Faculty of
department or school: Non UBC
department or school: Pediatrics, Department of
department or school: Psychiatry, Department of
data provider: DSpace
identifier citation: Children 12 (5): 648 (2025)
contributor: Children's Hospital (Vancouver, B.C.). Research Institute
creator: Paditz, Ekkehart
creator: Renner, Bertold
creator: Koch, Rainer
creator: Schneider, Barbara M.
creator: Schlarb, Angelika A.
creator: Ipsiroglu, Osman S.
issued: 2025-06-02T16:18:46Z
issued: 2025-05-16
description: Background: To date, it remains unclear which oral doses and preparation forms of melatonin should be recommended for children and adolescents with non-organic sleep disorders and autism spectrum disorder (ASD). We reviewed the current state of knowledge on this topic based on randomised placebo-controlled trials (RCTs) and diagnosis-related blood melatonin concentrations available in this age group. Method: Two investigators independently searched PubMed, PsycINFO, MEDLINE, and Cochrane CENTRAL on 1 March 2025 for the keywords “melatonin”, “autism”, and “randomised” in titles and abstracts in all languages, including an evaluation of the references of the reviews, systematic reviews, and meta-analyses published up to that date, some of which were based on searches in numerous databases. Based on this, additional in-depth searches were carried out in PubMed for pharmacokinetic, physiological, and pathophysiological data on melatonin in children and adolescents, with a special focus on ASD. Results: To date, five RCTs on non-organic sleep disorders in children and adolescents with the sole diagnosis of ASD or with subgroup analyses in the presence of several initial diagnoses such as ADHD, epilepsy, Smith–Magenis, or Fragile X syndrome are available. In these studies, rapid-release, non-delayed preparations were administered orally. In one of these studies, the clinical efficacy of a combination preparation with a sustained-release and a non-released active substance component was tested. Pharmacokinetic data with multiple determinations of melatonin concentrations in the blood are only available for children with ASD in the form of a case series (N = 9). Discussion: RCTs comparing the efficacy of delayed melatonin preparations with non-delayed rapid-release oral preparations are not yet available. Physiological data and clinical effects documented in five RCTs indicate that non-delayed melatonin preparations with an initial rapid onset of action are effective for no…
aggregated CHO: https://circle.library.ubc.ca/rest/handle/2429/91250
note: Academic Editor: FrancescaSantamariaReceived: 25 March 2025Revised: 29 April 2025Accepted: 10 May 2025Published: 16 May 2025Citation: Paditz, E.; Renner, B.; Koch,R.; Schneider, B.M.; Schlarb, A.A.;Ipsiroglu, O.S. The Pharmacokinetics,Dosage, Preparation Forms, andEfficacy of Orally AdministeredMelatonin for Non-Organic SleepDisorders in Autism SpectrumDisorder During Childhood andAdolescence: A Systematic Review.Children 2025, 12, 648. https://doi.org/10.3390/children12050648Copyright: © 2025 by the authors.Licensee MDPI, Basel, Switzerland.This article is an open access articledistributed under the terms andconditions of the Creative CommonsAttribution (CC BY) license(https://creativecommons.org/licenses/by/4.0/).Systematic ReviewThe Pharmacokinetics, Dosage, Preparation Forms, and Efficacyof Orally Administered Melatonin for Non-Organic SleepDisorders in Autism Spectrum Disorder During Childhood andAdolescence: A Systematic ReviewEkkehart Paditz 1,* , Bertold Renner 2 , Rainer Koch 3, Barbara M. Schneider 4, Angelika A. Schlarb 5and Osman S. Ipsiroglu 61 Centre for Applied Prevention/Zentrum für Angewandte Prävention, 01307 Dresden, Germany2 Institute of Clinical Pharmacology, Faculty of Medicine Carl Gustav Carus, Dresden University of Technology,01069 Dresden, Germany; bertold.renner@tu-dresden.de3 Formerly Institute for Medical Informatics and Biometry, Faculty of Medicine Carl Gustav Carus, DresdenUniversity of Technology, 01069 Dresden, Germany; rainer.koch.01@gmx.de4 Paediatric Sleep Medicine Centre in Foundation, Vancouver, BC V5Z 4H4, Canada;b.schneider@kinder-schlaf.de5 Faculty of Psychology and Sports Science, Bielefeld University, 33615 Bielefeld, Germany;angelika.schlarb@uni-bielefeld.de6 Interdisciplinary Sleep Program, Sleep/Wake-Behaviour Clinic, Departments of Pediatrics & Psychiatry,University of British Columbia, Vancouver, BC V6T 1Z4, Canada; oipsiroglu@bcchr.ca* Correspondence: praxis@paditz.euAbstract: Background: To date, it remains unclear …
has type: Article
is shown at: 10.14288/1.0449009
language: eng
peer review status: Reviewed
provider: Vancouver : University of British Columbia Library
publisher: Multidisciplinary Digital Publishing Institute
publisher DOI: 10.3390/children12050648
rights: CC BY 4.0
rights URI: https://creativecommons.org/licenses/by/4.0/
scholar level: Faculty
scholar level: Researcher
subject: melatonin in children and adolescents
subject: autism spectrum disorder
subject: sleep
subject: pharmacokinetics
subject: RCT
subject: non-delayed preparations
title: The Pharmacokinetics, Dosage, Preparation Forms, and Efficacy of Orally Administered Melatonin for Non-Organic Sleep Disorders in Autism Spectrum Disorder During Childhood and Adolescence : A Systematic Review
type: Text
identifier URI: http://hdl.handle.net/2429/91250